Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
Astegolimab (RG 6149) is a humanised IgG2 monoclonal antibody that targets the IL-33 receptor and inhibits IL-33 signalling. Astegolimab is used in the study of chronic obstructive pulmonary disease (COPD) and severe asthma in adults.
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor and inhibition of IL-31 and OSM signaling.Vixarelimab can be used to study severe nodular itch and idiopathic pulmonary fibrosis.
Flanvotumab (IMC-20D7S) is a humanized monoclonal antibody directed against tyrosinase-related protein (TYRP1).Flanvotumab exhibits potent antitumor activity and acts through natural killer-mediated and antibody-dependent cell-mediated cytotoxicity (ADCC).
Itepekimab (REGN-3500) is a potent monoclonal antibody against IL-33.Itepekimab reduces airway inflammation and associated tissue damage in in vivo experiments and can be used to study asthma.
Plozalizumab (MLN-1202) is a humanized selective and potent anti-CCR2 antibody.Plozalizumab has antitumor activity.Plozalizumab is used in the study of malignant melanoma.
Clesrovimab (MK1654) is an anti-respiratory syncytial virus protein F human monoclonal antibody for the prevention and treatment of respiratory syncytial virus infections.
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody targeting the CD70 antibody. Vorsetuzumab has anticancer activity and can enhance the macrophage-associated phagocytosis of kidney cancer cells and inhibit Burkitt lymphoma.
